CONTENTS

IMPORTANT NOTICE TO INVESTORS

This document is issued by the Company solely in connection with the [REDACTED] and the [REDACTED] and does not constitute an [REDACTED] to sell or a solicitation of an [REDACTED] to buy any security other than the [REDACTED] offered by this document pursuant to the [REDACTED]. This document may not be used for the purpose of making, and does not constitute, an [REDACTED] invitation in any other jurisdiction or in any other circumstances. No action has been taken to permit a [REDACTED] of the [REDACTED] in any jurisdiction other than Hong Kong and no action has been taken to permit the distribution of this document in any jurisdiction other than Hong Kong. The distribution of this document for purposes of a [REDACTED] and the [REDACTED] and [REDACTED] in other jurisdictions are subject to restrictions and may not be made except as permitted under the applicable securities laws of such jurisdictions pursuant to registration with or authorization by the relevant securities regulatory authorities or an exemption therefrom.

You should rely only on the information contained in this document to make your investment decision. The [REDACTED] is made solely on the basis of the information contained and the representations made in this document. We have not authorized anyone to provide you with information that is different from what is contained in this document. Any information or representation not contained nor made in this document must not be relied on by you as having been authorized by the Company, the Sole Sponsor, [the [REDACTED] the [REDACTED] the [REDACTED] any of the [REDACTED] and the [REDACTED], any of our or their respective directors, officers, employees, agents or representatives of any of them or any other parties involved in the [REDACTED]. Information contained on our website (www.yzybio.com) does not form part of this document.

	Page
EXPECTED TIMETABLE	iii
CONTENTS	vi
SUMMARY	1
DEFINITIONS	21
GLOSSARY OF TECHNICAL TERMS	34
FORWARD-LOOKING STATEMENTS	52

CONTENTS

RISK FACTORS	54
INFORMATION ABOUT THIS DOCUMENT AND THE [REDACTED]	142
DIRECTORS, SUPERVISORS AND PARTIES INVOLVED IN THE [REDACTED]	147
CORPORATE INFORMATION	153
INDUSTRY OVERVIEW	156
REGULATORY OVERVIEW	221
HISTORY, DEVELOPMENT AND CORPORATE STRUCTURE	253
BUSINESS	291
FINANCIAL INFORMATION	457
DIRECTORS, SUPERVISORS AND SENIOR MANAGEMENT	501
SHARE CAPITAL	526
SUBSTANTIAL SHAREHOLDERS	532
WAIVERS FROM STRICT COMPLIANCE WITH THE LISTING RULES AND EXEMPTION FROM COMPLIANCE WITH THE COMPANIES (WINDING UP AND MISCELLANEOUS PROVISIONS) ORDINANCE	536
FUTURE PLANS AND [REDACTED]	546
[REDACTED]	549
STRUCTURE OF THE [REDACTED]	562
HOW TO APPLY FOR [REDACTED]	574
APPENDIX I - ACCOUNTANTS' REPORT	I-1
APPENDIX II - UNAUDITED [REDACTED] FINANCIAL INFORMATION	II-1

CONTENTS

APPENDIX III	-	TAXATION AND FOREIGN EXCHANGE	III-1
APPENDIX IV	-	SUMMARY OF PRINCIPAL LEGAL AND REGULATORY PROVISIONS	IV-1
APPENDIX V	_	SUMMARY OF ARTICLES OF ASSOCIATION	V-1
APPENDIX VI	-	STATUTORY AND GENERAL INFORMATION	VI-1
APPENDIX VII	-	DOCUMENTS DELIVERED TO THE REGISTRAR OF COMPANIES IN HONG KONG AND AVAILABLE ON DISPLAY	VII_1
		AVAILABLE ON DISTLAY	v 11-